Back to top
more

Pacira BioSciences (PCRX)

(Real Time Quote from BATS)

$16.56 USD

16.56
218,943

-0.01 (-0.06%)

Updated Nov 4, 2024 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Pacira (PCRX) Down 7.6% Since Last Earnings Report?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacira (PCRX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Pacira (PCRX) impresses investors with both earnings and revenue beat in the fourth quarter.

5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

by Zacks Equity Research

Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

Why Pacira (PCRX) Could Beat Earnings Estimates Again

by Zacks Equity Research

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings

by Zacks Equity Research

Herbalife (HLF) is likely to gain from its direct-selling network, product portfolio and solid volumes. However, unfavorable currency movements and stiff competition may hurt the bottom line.

Madhu Goel headshot

Pacira's Study on Exparel Label Expansion Meets Endpoints

by Madhu Goel

Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.

Cara (CARA) Up on IDMC's Recommendation to Continue Trial

by Zacks Equity Research

Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.

Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com

by Zacks Equity Research

Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com

Sanghamitra Saha headshot

In Search of an Earnings Beat? Play These Top 5 Stocks

by Sanghamitra Saha

These top-ranked stocks may surpass bottom-line estimates in their next release.

Why Is Pacira (PCRX) Down 7.3% Since Last Earnings Report?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Lilly (LLY) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Top Ranked Momentum Stocks to Buy for November 9th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th

Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3

Pacira (PCRX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 342.86% and 5.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?

by Zacks Equity Research

Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.

Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher

by Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher

    by Zacks Equity Research

    Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares rise 6% on the day, amid huge volumes.

      Catalyst Pharmaceuticals (CPRX) Catches Eye: Stock Jumps 6.3%

      by Zacks Equity Research

      Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

        Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status

        by Zacks Equity Research

        Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.

          Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda

          by Zacks Equity Research

          Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.

            Molecular Templates Surges 50%, Inks Cancer Deal With Takeda

            by Zacks Equity Research

            Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.

              Implied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options

              by Zacks Equity Research

              Investors need to pay close attention to Pacira Pharmaceuticals (PCRX) stock based on the movements in the options market lately.

                United Therapeutics In-Licenses Rights to IPF Candidate

                by Zacks Equity Research

                United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.

                  Ironwood Stock Up, Heart Candidate Gets Fast Track Status

                  by Zacks Equity Research

                  The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.

                    Indrajit Bandyopadhyay headshot

                    Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study

                    by Indrajit Bandyopadhyay

                    Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.